期刊
ACS APPLIED MATERIALS & INTERFACES
卷 14, 期 15, 页码 17022-17031出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.1c23412
关键词
RNA interference; drug delivery; lipid nanoparticles; reactive oxygen species; corneal neovascularization
资金
- National Key R&D Program of China [2017YFA0103204, 2017YFA0208100]
- National Natural Science Foundation of China [81770887, 21778056, 22077125]
This study reports the design of a novel ROS-responsive lipid nanoparticle for enhanced RNAi in CNV treatment. The lipid nanoparticles efficiently deliver siRNA into cells and release siRNA in response to the upregulated ROS in CNV.
Corneal neovascularization (CNV) is a common disease that affects the vision ability of more than 1 million people annually. Small interfering RNA (siRNA) delivery nanoparticle platforms are a promising therapeutic modality for CNV treatment. However, the efficient delivery of siRNA into cells and the effective release of siRNA from delivery vehicles in a particular cell type challenge effective RNAi clinical application for CNV suppression. This study reports the design of a novel reactive oxygen species (ROS)-responsive lipid nanoparticle for siRNA delivery into corneal lesions for enhanced RNAi as a potential CNV treatment. We demonstrated that lipid nanoparticles could efficiently deliver siRNA into human umbilical vein endothelial cells and release siRNA for enhanced gene silencing by using the upregulated ROS of CNV to promote lipid nanoparticle degradation. Moreover, the subconjunctival injection of siRNA nanocomplexes into corneal lesions effectively knocked down vascular endothelial growth factor expression and suppressed CNV formation in an alkali burn model. Thus, we believe that the strategy of using ROS-responsive lipid nanoparticles for enhanced RNAi in CNV could be further extended to a promising clinical therapeutic approach to attenuate CNV formation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据